SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
+7.07%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$565M
AUM Growth
+$565M
(+3.4%)
Cap. Flow
-$19.1M
Cap. Flow
% of AUM
-3.38%
Top 10 Holdings %
Top 10 Hldgs %
52.66%
Holding
41
New
8
Increased
7
Reduced
20
Closed
4
Top Buys
| 1 |
Organon & Co
OGN
|
$16.7M |
| 2 |
Henry Schein
HSIC
|
$12.3M |
| 3 |
Bristol-Myers Squibb
BMY
|
$10.2M |
| 4 |
Biogen
BIIB
|
$8.24M |
| 5 |
Hologic
HOLX
|
$7.86M |
Top Sells
| 1 |
LivaNova
LIVN
|
$10.7M |
| 2 |
Pfizer
PFE
|
$8.84M |
| 3 |
Centene
CNC
|
$8.68M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$7.75M |
| 5 |
Revvity
RVTY
|
$7.69M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pfizer
PFE
$141B
| $44.6M | 7.91% | 1,139,985 -225,778 | -17% | -$8.84M |
|
2
Gilead Sciences
GILD
$140B
| $39.8M | 7.04% | 577,368 -101,265 | -15% | -$6.97M |
|
3
Merck
MRK
$210B
| $35.4M | 6.27% | 455,447 -50,729 | -10% | -$3.95M |
|
|
4
Bristol-Myers Squibb
BMY
$96B
| $35M | 6.2% | 523,493 +152,431 | +41% | +$10.2M |
|
5
Medtronic
MDT
$119B
| $26M | 4.6% | 209,128 -20,195 | -9% | -$2.51M |
|
|
6
Biogen
BIIB
$19.4B
| $25.3M | 4.48% | 73,043 +23,783 | +48% | +$8.24M |
|
7
Incyte
INCY
$16.5B
| $23.9M | 4.23% | 284,145 -56,906 | -17% | -$4.79M |
|
8
Bruker
BRKR
$5.16B
| $23.3M | 4.13% | 306,650 -71,117 | -19% | -$5.4M |
|
9
Becton Dickinson
BDX
$55.3B
| $23M | 4.08% | 94,681 -7,106 | -7% | -$1.73M |
|
10
Cardinal Health
CAH
$35.5B
| $21.1M | 3.73% | 368,931 +44,467 | +14% | +$2.54M |
|
|
NUVA
11
DELISTED
NuVasive, Inc.
NUVA
| $19.9M | 3.53% | 293,754 +14,495 | +5% | +$982K |
|
12
Boston Scientific
BSX
$156B
| $18.7M | 3.31% | 436,406 +54,870 | +14% | +$2.35M |
|
13
Elevance Health
ELV
$71.8B
| $17M | 3.02% | 44,624 -12,147 | -21% | -$4.64M |
|
|
14
Centene
CNC
$14.3B
| $16.7M | 2.96% | 229,410 -119,041 | -34% | -$8.68M |
|
15
CVS Health
CVS
$92.8B
| $16.7M | 2.96% | 200,441 -39,022 | -16% | -$3.26M |
|
|
16
Organon & Co
OGN
$2.45B
| $16.7M | 2.96% | +552,232 | New | +$16.7M |
|
17
Baxter International
BAX
$12.7B
| $15.5M | 2.75% | 192,739 -14,212 | -7% | -$1.14M |
|
18
Elanco Animal Health
ELAN
$9.12B
| $13.8M | 2.44% | 396,478 -23,501 | -6% | -$815K |
|
|
19
Henry Schein
HSIC
$8.44B
| $12.3M | 2.18% | +165,721 | New | +$12.3M |
|
20
Labcorp
LH
$23.1B
| $12M | 2.13% | 43,547 -2,194 | -5% | -$605K |
|
21
Ionis Pharmaceuticals
IONS
$6.79B
| $10.5M | 1.86% | 263,488 -190,662 | -42% | -$7.61M |
|
|
22
Revvity
RVTY
$10.5B
| $10.4M | 1.85% | 67,661 -49,806 | -42% | -$7.69M |
|
23
Bio-Rad Laboratories Class A
BIO
$8.06B
| $10.4M | 1.84% | 16,136 -3,421 | -17% | -$2.2M |
|
24
Alnylam Pharmaceuticals
ALNY
$58.5B
| $9.84M | 1.74% | 58,017 -1,772 | -3% | -$300K |
|
25
Perrigo
PRGO
$3.27B
| $9.39M | 1.66% | 204,732 -146 | -0.1% | -$6.69K |
|